These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Advanced case of PKDL due to delayed treatment: A rare case report. Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500 [TBL] [Abstract][Full Text] [Related]
4. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277 [TBL] [Abstract][Full Text] [Related]
5. Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis. Kusumesh R; Ambasta A; Arya LK; Mohan N; Sinha BP; Ravidas V Br J Ophthalmol; 2021 Nov; 105(11):1497-1503. PubMed ID: 32962993 [TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665 [TBL] [Abstract][Full Text] [Related]
7. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis. Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451 [TBL] [Abstract][Full Text] [Related]
8. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478 [TBL] [Abstract][Full Text] [Related]
9. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states. Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161 [TBL] [Abstract][Full Text] [Related]
10. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine. Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349 [TBL] [Abstract][Full Text] [Related]
11. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis. Ansari NA; Ramesh V; Salotra P Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1160-2. PubMed ID: 18639311 [TBL] [Abstract][Full Text] [Related]
12. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis. Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208 [TBL] [Abstract][Full Text] [Related]
13. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India. Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204 [TBL] [Abstract][Full Text] [Related]
14. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis. Ghosh S; Das NK; Mukherjee S; Mukhopadhyay D; Barbhuiya JN; Hazra A; Chatterjee M Am J Trop Med Hyg; 2015 Oct; 93(4):767-9. PubMed ID: 26175030 [TBL] [Abstract][Full Text] [Related]
15. A case of miltefosine responsive pleomorphic post kala-azar dermal leishmaniasis. Pal D; Naskar A; Ghosh MK Braz J Infect Dis; 2013; 17(5):610-2. PubMed ID: 24012431 [No Abstract] [Full Text] [Related]
16. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. Sundar S; Singh A; Chakravarty J; Rai M ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839 [TBL] [Abstract][Full Text] [Related]
17. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Kumar D; Ramesh V; Verma S; Ramam M; Salotra P Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997 [No Abstract] [Full Text] [Related]
18. Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment. Maruf S; Nath P; Islam MR; Aktar F; Anuwarul A; Mondal D; Basher A PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006781. PubMed ID: 30222747 [TBL] [Abstract][Full Text] [Related]
19. Blindness following visceral leishmaniasis: a neglected post-kala-azar complication. Khalil EA; Musa AM; Younis BM; Elfaki ME; Zijlstra EE; Elhassan AM Trop Doct; 2011 Jul; 41(3):139-40. PubMed ID: 21676981 [TBL] [Abstract][Full Text] [Related]
20. Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient. Abongomera C; Battaglioli T; Adera C; Ritmeijer K Int J Infect Dis; 2019 Apr; 81():221-224. PubMed ID: 30790722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]